Safinamide

From Self-sufficiency
Jump to: navigation, search
Safinamide
File:Safinamide.svg
Systematic (IUPAC) name
N2-{4-[(3-fluorobenzyl)oxy]benzyl}-L-alaninamide
Identifiers
CAS Number 133865-89-1
ATC code none
PubChem CID 131682
Synonyms (2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl]methylamino]propanamide
Chemical data
Formula C17H19FN2O2
Molar mass 302.34 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Safinamide is a candidate drug against Parkinson's disease with multiple methods of action.[1] In 2007, a Phase III clinical trial was started.[2] It will be marketed by Merck-Serono.

Possible additional uses are restless legs syndrome (RLS) and epilepsy.[3] As of 2008, they are in Phase II.

Methods of action

Parkinson and RLS relevant mechanisms

Safinamide is a monoamine oxidase B inhibitor, reducing degradation of dopamine.

It is a glutamate release inhibitor.

It seems to inhibit dopamine reuptake.

Other mechanisms

Furthermore, safinamide blocks sodium and calcium channels.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
  1. Fariello, RG (2007). "Safinamide". Neurotherapeutics. 4 (1): 110–116. doi:10.1016/j.nurt.2006.11.011. PMID 17199024. 
  2. Study of Safinamide in Early Parkinson's Disease as Add-on to Dopamine Agonist (MOTION)
  3. Chazot, PL (2007). "Drug evaluation: Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome". Current opinion in investigational drugs. 8 (7): 570–579. PMID 17659477.